Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Background Patients living with cancer are at a significantly increased risk of morbidity and
mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV …

Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID …

Summary Background The omicron (B. 1.1. 529) variant of SARS-CoV-2 is highly
transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due …

Resident memory T cells (TRM) present at the respiratory tract may be essential to enhance
early SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term …

Purpose People living with cancer and haematological malignancies are at an increased
risk of hospitalisation and death following infection with acute respiratory syndrome …

Summary Background Breakthrough SARS-CoV-2 infections following vaccination against
COVID-19 are of international concern. Patients with cancer have been observed to have …

Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …

Omicron, the SARS-CoV-2 B. 1.1. 529 variant of concern (VOC), was first detected in
southern Africa in November, 2021, and its BA. 1 sublineage is now dominant in the UK …

Patients with blood cancer continue to have a greater risk of inadequate immune responses
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …